BioWorld

IFNα-like small molecules successfully inhibit HBV replication

It’s known that interferon-alpha (IFNα) activates interferon-stimulated genes (ISGs) and disrupts the hepatitis B virus (HBV) replication cycle. Pegylated (PEG)-IFNα has been widely used for its ...
News Medical

Researchers develop new approach for studying HBV in the lab

Hepatitis C and hepatitis B viruses both attack the liver, eventually causing deadly cirrhosis or cancer. But while antivirals can cure 95 percent of HCV infections, its cousin HBV has long eluded ...
EurekAlert!

Paclitaxel-induced immune dysfunction and activation of transcription factor AP-1 facilitate Hepatitis B virus replication

Hepatitis B virus (HBV) reactivation is commonly observed in individuals with chronic HBV infection undergoing antineoplastic drug therapy. Paclitaxel (PTX) treatment has been identified as a ...
Nasdaq

Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus

Trial will evaluate Assembly’s core inhibitor candidate, vebicorvir, with Arbutus’ RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy SOUTH SAN FRANCISCO, Calif., and WARMINSTER, Pa ...
EurekAlert!

The relationship between viral replication and the severity of hepatic necroinflammatory damage changed before HBeAg loss in patients with chronic hepatitis B virus infection

A negative relationship between viral replication and liver inflammation in HBeAg-positive patients with high HBV DNA, which changed to a positive relationship for those HBeAg-positive patients with ...
Nasdaq

Assembly Biosciences Reports Positive Phase 1b Results for ABI-4334 in Chronic HBV Infection, Supporting Collaboration with Gilead Sciences

Assembly Biosciences reported positive Phase 1b results for ABI-4334 in chronic HBV, showing strong antiviral activity and favorable safety. Assembly Biosciences, Inc. has announced positive results ...